Skip to content
Study details
Enrolling now

Cannabidiol for Reduction of Brain Neuroinflammation

Massachusetts General Hospital
NCT IDNCT05066308ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

80

Study length

about 4.9 years

Ages

18–75

Locations

1 site in MA

About this study

Researchers are testing whether cannabidiol (CBD), a treatment, can reduce brain inflammation in adults with chronic pain and/or depression. The trial will last 1806 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take CBD
PhasePhase 2
DrugCBD

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

cannabinoid

Endpoints

Secondary: Change in Clinical Pain Ratings, Change in Depressive Symptoms, Change in Pain Bothersomeness, Correlation Between Reductions in Limbic [11C]PBR28 PET Signal and Reductions in Depressive Symptoms, Correlation Between Reductions in Thalamic [11C]PBR28 PET Signal and Reductions in Clinical Pain Ratings, Patient Global Impression of Change

Body systems

Psychiatry / Mental Health